John McShane, MS’ Post

"Nearly 100 years after the discovery of penicillin, we're on the brink of a "post-antibiotic era, with rising levels of bacteria resistant to even our last resort antibiotics." When it comes to advancing the future of medical therapies, solutions are often far from simple, but that's not stopping Professor Lara Malins from the ANU Research School of Chemistry. And her achievements are not going unnoticed. Professor Malin's work has been awarded a prestigious $8 million fellowship from Snow Medical to help in her fight against some of the globe's most pressing health challenges, including antimicrobial resistance and cancer, and to advance new life-saving medical therapies. Read more about her inspiring work: https://lnkd.in/gwf87YG8

The ALTTO and NeoALTTO trials – together involving more than 8,000 patients and establishing a huge prospective collection of biological materials for translational research – are a testimony to the strength and richness in terms of scientific expertise, creativity, and flexibility of BIG’s network of research groups to conduct complex international clinical studies. They were coordinated by BIG, the Institut Jules Bordet – Clinical Trials Support Unit, Frontier Science Scotland, and SOLTI in collaboration with GSK and Novartis. Learn more on this BIG achievement here 👉 https://lnkd.in/eYgndBF5 #BIGagainstbc #breastcancer #Breastcancerresearch

A day to remember how important research is for science and, even more so, for people’s lives. Advocating for more clinical trials and safe data that can improve people’s lives and bring cures to rare diseases. #duchennemusculardystrophy #beckermusculardystrophy

Prism.bio recognizes that creating ontologies creates more space for discovery. So when an ontology for digital health technologies (DHTs) did not yet exist, we partnered with Janssen Clinical Innovation to create it. This ontology led to a data resource that helps pharma companies choose the optimal DHT for their clinical trial.  Explore the DHT ontology: https://bit.ly/3Qj0LDo #Pharma #ClinicalTrial #Ontology Jason LaRoche Bert Hartog

Last month, the Proxima Book Club read The Immortal Life of Henrietta Lacks, which, as a regulatory and clinical research company, was particularly relevant. If you’re unfamiliar with the case of Henrietta Lacks…her cancer cells were harvested without consent in 1951, and they have played a monumental role in scientific advancements since. Her story underscores the significance of Good Clinical Practice (GCP), an ethical and scientific quality standard for designing, conducting, recording, and reporting trials involving human subjects. These guidelines ensure that the rights, safety, and well-being of trial subjects are protected and that the clinical trial data are credible. In 1951, there weren't clear rules and standards like we have today regarding informed consent for tissue collection and use. Today, if tissues are removed during a medical procedure, they could potentially be used for research purposes, provided they are anonymized and the patient has not explicitly objected. However, to use identifiable tissue samples(like HeLa) specifically for research, explicit informed consent would typically be required. While the worls and many companies benefitted from HeLa cells over the years, Henrietta’s family did not. Last week, the family reached a confidential settlement with Thermo Fisher Scientific Inc, a company accused of unjustly enriching itself by commercializing Lacks' cells long after their origin became known. The resolution was reached after prolonged negotiations in a federal courthouse in Baltimore. Both parties expressed satisfaction with the outcome but declined to comment further. #gcp #clinicalresearch #biology #medicine

Liquid biopsy + cfDNA + methylome + genome? ..this webinar is for you!

JOH June issue, focusing on #ovary basic science and clinical studies, is online published! Thanks to all the authors and peer reviewers who made this possible! National Society for Histotechnology Taylor & Francis Group

Understanding #INOCA & it’s impact on real life Watch the INOCA International series on these important topics.

We love working together with our #partners within the IMMUcan consortium!   Today, we highlight our collaboration with Cliniques universitaires Saint-Luc in Brussels. Why is this partnership so important? Dr Philippe Stevens, PhD candidate, tells you more about the team’s experience in working with IMMUcan:   “It’s a real pleasure to collaborate with the IMMUcan consortium, which offers us the opportunity to broaden our knowledge and the field of our #researchprojects. This will allow us to go beyond our primary assumptions and explore a new side of the tumour microenvironment in metastatic #colorectalcancer.”   Curious to learn more about the project? Go to immucan.eu

➡️ I am really excited to see the first publication of the EDASP cohort. ➡️For the last 5 years, I´ve been pushing really hard as its principal investigator to make this independent cohort study a reality. ➡️This work would not have been possible without the invaluable support of amazing and generous collaborators and friends such as Nehal Mehta Joel M Gelfand MD MSCE Maru G. Barderas Leticia Fernandez Friera Jorge Solis Martin Carlota B. Abbad-Jaime de Aragón @Emilio Berna ➡️The EDSAP study aims to identify new molecular and imaging markers associated with the presence of atherosclerosis and its progression in psoriasis and the evaluation of the impact of antiinflammatory therapies in athero. First papers comming soon!!!! #psoriasis #research #atherosclerosis #comorbidities